Increased Healthcare Resource Use and Costs After Discontinuation of Liraglutide in Patients with Type 2 Diabetes from a Commercial- and Medicaid-Insured Claims Database.
Chioma UzoigweJosh NooneYuanjie LiangSarah Naz AliCory GamblePublished in: Diabetes therapy : research, treatment and education of diabetes and related disorders (2022)
Patients who discontinued liraglutide showed increases in HCRU; costs, mainly driven by outpatient cost; and HbA1c within 12 months, emphasizing the importance of treatment optimization on clinical and economic outcomes in patients with T2D.